ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2686

Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis

Kunihiro Ichinose1, Mineaki Kitamura2, Shuntaro Sato3, Keita Fujikawa4, Yoshiro Horai5, Naoki Matsuoka6, Masahiko Tsuboi6, Fumiaki Nonaka7, Masataka Umeda1, Tomohiro Koga8, Takashi Igawa8, Tomoya Nishino2 and Atsushi Kawakami8, 1Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan, 3Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan, 4Japan Community Health care Organization Isahaya General Hospital, Nagasaki, Japan, 5Department of Rheumatology, Clinical Research Center, NHO Nagasaki Medical Center, Omura, Japan, 6Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan, 7Department of Internal Medicine, Sasebo City General Hospital, Sasebo, Japan, 8Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Lupus nephritis (LN) is a most important predictor of morbidity and mortality in patients with systemic lupus erythematosus (SLE).Histopathology samples from patients with LN can demonstrate injury to nearly any cell type, including the mesangial, endothelial, podocyte, tubulointerstitial and vascular involvement associated with different pathogeneses, clinical presentations, therapeutic responses, and outcomes in LN patients. Podocytes are epithelial cells that provide the glomerular filtration barrier with foot processes and slit diaphragms. The morphological change with diffuse effacement of the foot processes is correlated with proteinuria in patients with LN. It has also been shown that in patients with nephrotic LN, foot process effacement estimated by the foot process width (FPW) was more extensive than in patients with non-nephrotic LN.We evaluated the possible association between podocyte injury and clinical features in LN.

Methods:

We studied 73 patients with LN who underwent a renal biopsy at our hospital or a community hospital in 1993–2016. We collected the data of clinico-pathological parameters and assessed the FPW for evaluating podocyte effacement. We retrospectively analyzed the complete renal remission (CR) rate at 6 and 12 months after induction therapy and determined the predictive factors for CR. Univariate and multivariable competing risks regression analyses were used to determine the predictive factors of CR. Decision tree models predicting CR were built with the Classification and Regression Trees (CART) algorithm.

Results:

At 6 and 12 months after induction therapy, 34 patients (46.6%) and 47 patients (64.3%) achieved CR, respectively. The multivariate analysis revealed that female gender (OR 5.288, 95%CI: 1.197–37.29, p=0.0267) and FPW (OR 0.999, 95%CI: 0.997–0.999, p=0.0150) for predicting CR at 6 months and lymphocyte counts (OR 1.002, 95%CI: 1.001–1.003, p=0.0028) and FPW (OR 0.998, 95%CI: 0.996–0.999, p=0.0027) for predicting CR at 12 months were significant.The median FPW was 1088 nm (IQR 895–1465 nm) in the total group of 73 patients. The degree of foot process effacement was significantly different among the various types of LN (p=0.0007): 701 nm (IQR 546–902 nm) in class I, 817 nm (IQR 685–1056 nm) in class II, 921 nm (IQR 711–1145 nm) in pure class III, 1294 nm (IQR 1086–1804 nm) in pure class IV, 1283 nm (IQR 899–1484 nm) in pure class V, and 1421 nm (IQR 887–1976 nm) in the combined group (class III + V and IV + V). We found that there was a moderate correlation between the individual FPW value and the amount of proteinuria (r=0.3554, p=0.00022). There was also a significant correlation between the individual FPW and serum albumin (r= −0.4757, p<0.0001) and between the individual FPW and the index of activity (0–24) (r=0.4908, p<0.0001).The cut-off point determined by the CART algorithm showed that FPW <908.3 nm provide the best performance to predict patients who achieve CR at 12 months.

Conclusion:

We found that the lymphocyte count and/or the foot process width are prognostic markers for the achievement of a CR at 6 and 12 months after induction therapy for lupus nephritis. The pathological role of the FPW is still unknown, but it may reflect the degree of podocyte function.


Disclosure: K. Ichinose, None; M. Kitamura, None; S. Sato, None; K. Fujikawa, None; Y. Horai, None; N. Matsuoka, None; M. Tsuboi, None; F. Nonaka, None; M. Umeda, None; T. Koga, None; T. Igawa, None; T. Nishino, None; A. Kawakami, None.

To cite this abstract in AMA style:

Ichinose K, Kitamura M, Sato S, Fujikawa K, Horai Y, Matsuoka N, Tsuboi M, Nonaka F, Umeda M, Koga T, Igawa T, Nishino T, Kawakami A. Podocyte Foot Process Width Is a Prediction Marker for Complete Renal Remission at 6 and 12 Months after Induction Therapy in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/podocyte-foot-process-width-is-a-prediction-marker-for-complete-renal-remission-at-6-and-12-months-after-induction-therapy-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/podocyte-foot-process-width-is-a-prediction-marker-for-complete-renal-remission-at-6-and-12-months-after-induction-therapy-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology